Patents Assigned to Merck
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20200270346
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: May 15, 2020
    Publication date: August 27, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
  • Oxazolidinone compounds and methods of use thereof as antibacterial agents
    Patent number: 10752621
    Abstract: The present invention relates to oxazolidinone Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at least one oxazolidinone compound of the invention. The invention also provides methods for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis comprising administering a therapeutically effective amount of an oxazolidinone of the invention and/or a pharmaceutically acceptable salt thereof, or a composition comprising such compound and/or salt.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: August 25, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jing Su, Lihu Yang, Takao Suzuki
  • Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
    Patent number: 10751412
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Toll-like receptor 9 (TLR9) agonist that is a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 25, 2020
    Assignees: MERCK SHARP & DOHME CORP., DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Ying Yu, Andrew Evan Denker, Svetlana Sadekova, Uyen Truong Phan, Robert A. Kastelein, David Ross Kaufman, Robert L. Coffman, Cristiana Guiducci, Robert S. Janssen
  • Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use
    Patent number: 10752587
    Abstract: In its many embodiments, the present invention provides certain substituted bispiperidinyl compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein ring A, ring B, R1, R2, R3, L, R4, X, Z, Li, Q and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-? receptor (LXR?) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: August 25, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael T. Rudd, David Jonathan Bennett, Jenny Wai, Zhaoyang Meng
  • POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS
    Publication number: 20200263091
    Abstract: The present invention relates to a mixture comprising a not fully aromatic polymerisabe compound and a polymerisable photoinitiator, to liquid-crystal (LC) media comprising them, and to the use of the polymerisable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the polymer sustained alignment type.
    Type: Application
    Filed: September 26, 2018
    Publication date: August 20, 2020
    Applicant: Merck Patent GmbH
    Inventors: Qiong TONG, Dmitry USHAKOV, Helga HAAS, Steffen GNAUCK, Thorsten RACHOR, Sven SCHUEPFER, Simon MUNDINGER
  • Factor XIIa Inhibitors
    Publication number: 20200262831
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIIa inhibitors.
    Type: Application
    Filed: November 13, 2017
    Publication date: August 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jacqueline D. Hicks, Brian Alexander McKittrick, Brent R. Whitehead, Matthew Lombardo, Xiaoqing Han, Jerry A. Taylor, Hong Dong Chu, Sung-Sau So, Peter Orth, Zhicai Wu
  • HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS
    Publication number: 20200261421
    Abstract: The present invention is directed to compounds of Formula I, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.
    Type: Application
    Filed: December 19, 2017
    Publication date: August 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Brian McKittrick, John P. Caldwell, John A. McCauley, Henry Vaccaro, Tin-Yau Chan, Hyunjin Kim, Elizabeth Smith, Liwu Hong, Tanweer Khan, Shihong Ying, Hongwu Wang
  • BENZIMIDAZOLES AND INDOLES AS TARO INHIBITORS
    Publication number: 20200261410
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Application
    Filed: December 13, 2016
    Publication date: August 20, 2020
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: John P. CALDWELL, Ginny Dai HO, Sookhee N. HA, Sandra J. KOSEOGLU, Marc A. LABROLI, Sang Ho LEE, Christina MADSEN-DUGGAN, Mihir MANDAL, Jianping PAN, Weidong PAN, Terry ROEMER, Jin SU, Christopher Michael TAN, Zheng TAN, Hao WANG, Christine YANG, Shu-Wei YANG
  • STABLE FORMULATIONS OF ANTI-CTLA4 ANTIBODIES ALONE AND IN COMBINATION WITH PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20200262922
    Abstract: The invention relates to stable formulations comprising antibodies or antigen binding fragments thereof that bind to cytotoxic T lymphocyte associated antigen 4 (CTLA4), optionally further containing an anti-human programmed death receptor 1 (PD-1) antibody or antigen binding fragment thereof. Also provided are methods of treating various cancers and chronic infections with the formulations of the invention.
    Type: Application
    Filed: May 1, 2018
    Publication date: August 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Soumendu Bhattacharya, Chakravarthy Nachu Narasimhan, Manoj K. Sharma, Xiaoyu Yang, Arnab De, Rubi Burlage, Jason K. Cheung
  • HETEROARYL ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
    Publication number: 20200262826
    Abstract: The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation (I).
    Type: Application
    Filed: September 14, 2018
    Publication date: August 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Brendan M. Crowley, Peter J. Manley, William D. Shipe
  • HYDROPHILIC COMPOUNDS FOR OPTICALLY ACTIVE DEVICES
    Publication number: 20200262805
    Abstract: The present invention relates to novel compounds, particularly to hydrophilic compounds, comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices. The present application also relates to ophthalmic devices comprising such compounds.
    Type: Application
    Filed: May 7, 2020
    Publication date: August 20, 2020
    Applicant: Merck Patent GmbH
    Inventors: Lars DOBELMANN-MARA, Stefan RIEDMUELLER, Martin SCHRAUB
  • OXAZOLIDINONES AS TARO INHIBITORS
    Publication number: 20200261436
    Abstract: Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infections, including gram negative bacterial infections and gram positive bacterial infections such as MRSA and MRSE, alone or in combination with a ?-lactam antibiotic.
    Type: Application
    Filed: December 13, 2016
    Publication date: August 20, 2020
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: John P. CALDWELL, Reynalda DE JESUS, Fa-Xiang DING, Charles J. GIll, Ginny Dai HO, Sookhee N. HA, Sandra J. KOSEOGLU, Marc A. LABROLI, Sang Ho LEE, Christina MADSEN-DUGGAN, Mihir MANDAL, Terry ROEMER, Jing SU, Christopher Michael TAN, Zheng TAN, Haifeng TANG, Hao WANG, Christine YANG, Shu-Wei YANG
  • PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS
    Publication number: 20200261365
    Abstract: A process for preparing and isolating pharmaceutical active ingredient particles having a particle size of between about 0.1 and 30 microns, wherein a slurry comprising the active ingredient and one or more pharmaceutically acceptable excipients is fed into a thin film evaporator under suitable conditions for less than 10 minutes sufficient to generate solid matrix particles comprising active ingredient and one or more excipients, wherein the particles have less than 5% residual solvent.
    Type: Application
    Filed: December 13, 2016
    Publication date: August 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Luke R. Schenck, David J. Lamberto, Joseph L. Kukura, II, Francisco J. Guzman, Aaron Cote, Athanas Koynov
  • HETEROCYCLIC SPIRO COMPOUNDS
    Publication number: 20200266364
    Abstract: The present invention relates to spiro compounds containing electron-conducting groups and to electronic devices, in particular organic electroluminescent devices, comprising these compounds.
    Type: Application
    Filed: May 7, 2020
    Publication date: August 20, 2020
    Applicant: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Elvira Montenegro, Anja Jatsch, Christof Pflumm, Jonas Valentin Kroeber, Tobias Grossman, Thomas Eberle, Lars Dobelmann-Mara
  • FORMULATIONS CONTAINING KETONES COMPRISING NON-AROMATIC CYCLES
    Publication number: 20200266349
    Abstract: The present invention relates to formulations for the preparation of organic electronic devices which comprise at least one specific ketone solvent containing a non aromatic cycle and at least one organic functional material, preferably selected from organic conductors, organic semiconductors, organic fluorescent compounds, organic phosphorescent compounds, organic light-absorbent compounds, organic light-sensitive compounds, organic photosensitisation agents and other organic photoactive compounds, selected from organometallic complexes of transition metals, rare earths, lanthanides and actinides.
    Type: Application
    Filed: November 11, 2016
    Publication date: August 20, 2020
    Applicant: Merck Patent GmbH
    Inventors: GAELLE BEALLE, Christoph LEONHARD, Hsin-Rong TSENG, Irina MARTYNOVA, Aurelie LUDEMANN
  • INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    Publication number: 20200262836
    Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
    Type: Application
    Filed: March 25, 2020
    Publication date: August 20, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: CRAIG A. COBURN, STEVEN W. LUDMERER, KUN LIU, Hao Wu, Richard Soll, Bin Zhong, Jian Zhu
  • CYANOPYRIMIDINE DERIVATIVES
    Publication number: 20200262795
    Abstract: The present invention relates to compounds of formula M in which RM has the meaning indicated in claim 1, to liquid crystal mixture comprising the same, to the use of these liquid-crystal media, in particular in components for high-frequency technology, and to components of this type which contain media according to the invention, and to the production and use of these components. The components according to the invention are suitable, in particular, as phase shifters in the microwave and millimetre wave region, for microwave and millimetre wave array antennae and very particularly for so-called tunable “reflectarrays”.
    Type: Application
    Filed: March 22, 2017
    Publication date: August 20, 2020
    Applicant: Merck Patent GmbH
    Inventors: Matthias BREMER, Atsutaka MANABE
  • Alkenyl (perfluoroalkyl) phosphinic acids
    Patent number: RE48165
    Abstract: The invention relates to alkenyl(perfluoroalkyl)phosphinic acids, to the preparation and intermediates thereof, to the use thereof as monomers for the preparation of oligomers and/or polymers, to the corresponding oligomers/polymers, to the corresponding support materials comprising the oligomers/polymers, and to the use thereof as ion exchangers, as catalysts or extraction medium and corresponding salts thereof.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: August 18, 2020
    Assignee: Merck Patent GmbH
    Inventors: Nikolai (Mykola) Ignatyev, Michael Schulte, Karsten Koppe, Vural Bilir, Walter Frank
  • Packaging
    Patent number: D893998
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: August 25, 2020
    Assignee: Merck KGaA
    Inventors: Mark Hinkle, Jeffrey Whitford
  • Packaging
    Patent number: D893999
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: August 25, 2020
    Assignee: Merck KGaA
    Inventors: Mark Hinkle, Jeffrey Whitford